ADMA Biologics Under Investigation for Potential Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy ADMA?
Source: Globenewswire
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, as allegations arise that the reported 20% revenue growth in 2025 may have been artificially inflated through channel stuffing, indicating serious concerns about the company's financial transparency.
- Revenue Growth Scrutiny: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly allowed the company to book revenue that was not genuinely realized; without this scheme, the company would have faced a 3% revenue decline in 2025, severely impacting investor confidence.
- Stock Price Plunge: Following the investigation and the report's findings, ADMA Biologics' stock price plummeted by 29% over two trading days, falling from $13.59 per share on March 23 to $9.63 per share on March 25, reflecting market concerns regarding the company's financial health and future prospects.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, indicating strong support for affected shareholders and potentially leading to increased legal actions seeking compensation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Under Investigation for Potential Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme, with actual growth potentially being a decline of 3%, raising serious concerns about the company's financial practices.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed these channel stuffing allegations, ADMA Biologics' stock price fell by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market skepticism regarding the company's financial integrity.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency basis, emphasizing their commitment to protecting shareholder rights and interests in light of these serious allegations.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, encouraging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme, potentially masking a real revenue decline of 3% instead.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed the channel stuffing practices, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market concerns over its financial integrity.
- Legal Implications: Investors may have legal recourse, with BFA offering representation on a contingency basis, highlighting a commitment to protecting investor rights while potentially impacting ADMA's future financing capabilities.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics and its executives have engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, highlighting serious concerns regarding corporate governance.
- Short Report Allegations: A short report published by Culper Research on March 24, 2026, claims that ADMA's reported growth is fictitious, driven primarily by channel stuffing and undisclosed related-party distributors, estimating a 3% revenue decline in 2025 versus a reported 20% growth, which triggered a strong market reaction.
- Stock Price Volatility: Following the release of the short report, ADMA's stock price fell by 16.63% to close at $11.33 per share on March 24, 2026, and then dropped another 13.91% to $8.29 per share on March 26, 2026, after Cantor Fitzgerald downgraded the stock, reflecting extreme investor anxiety about the company's outlook.
- Withdrawal of Financial Guidance: On May 6, 2026, ADMA withdrew its long-term financial guidance, citing evolving competitive dynamics in the U.S. plasma products and immunoglobulin market, leading to a further 15.97% drop in stock price to $8.47 per share the following day, indicating the company's vulnerable position in the market.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potential securities claims due to allegations of misleading business information, putting shareholders at risk of significant losses.
- Stock Price Plunge Impact: On March 24, 2026, ADMA Biologics' stock fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, directly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for affected investors, with no out-of-pocket fees required, thereby lowering the barrier for participation in the lawsuit.
- Law Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, raising concerns about the authenticity of the reported 20% revenue growth in 2025, which could undermine investor confidence.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly inflated revenue figures; without this scheme, the company would have faced a 3% revenue decline in 2025 instead of the reported growth.
- Stock Price Plunge: Following these allegations, ADMA Biologics' stock price dropped by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding its financial stability.
- Legal Options for Investors: Investors are encouraged to submit their information for potential legal recourse, with BFA offering representation on a contingency fee basis, thereby reducing the financial burden on affected shareholders and potentially providing avenues for compensation.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against ADMA Biologics for allegedly issuing misleading business information, indicating significant legal risks that could undermine shareholder confidence and stock performance.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, reflecting market concerns over the company's financial transparency.
- Class Action Preparation: Rosen Law Firm is preparing a class action against ADMA, allowing investors to seek compensation without upfront costs, which could impose greater financial strain and reputational damage on the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise, which may encourage more investors to join the lawsuit.
See More
ADMA Biologics Under Investigation for Potential Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme, with actual growth potentially being a decline of 3%, raising serious concerns about the company's financial practices.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed these channel stuffing allegations, ADMA Biologics' stock price fell by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market skepticism regarding the company's financial integrity.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency basis, emphasizing their commitment to protecting shareholder rights and interests in light of these serious allegations.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, encouraging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme, potentially masking a real revenue decline of 3% instead.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed the channel stuffing practices, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market concerns over its financial integrity.
- Legal Implications: Investors may have legal recourse, with BFA offering representation on a contingency basis, highlighting a commitment to protecting investor rights while potentially impacting ADMA's future financing capabilities.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics and its executives have engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, highlighting serious concerns regarding corporate governance.
- Short Report Allegations: A short report published by Culper Research on March 24, 2026, claims that ADMA's reported growth is fictitious, driven primarily by channel stuffing and undisclosed related-party distributors, estimating a 3% revenue decline in 2025 versus a reported 20% growth, which triggered a strong market reaction.
- Stock Price Volatility: Following the release of the short report, ADMA's stock price fell by 16.63% to close at $11.33 per share on March 24, 2026, and then dropped another 13.91% to $8.29 per share on March 26, 2026, after Cantor Fitzgerald downgraded the stock, reflecting extreme investor anxiety about the company's outlook.
- Withdrawal of Financial Guidance: On May 6, 2026, ADMA withdrew its long-term financial guidance, citing evolving competitive dynamics in the U.S. plasma products and immunoglobulin market, leading to a further 15.97% drop in stock price to $8.47 per share the following day, indicating the company's vulnerable position in the market.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potential securities claims due to allegations of misleading business information, putting shareholders at risk of significant losses.
- Stock Price Plunge Impact: On March 24, 2026, ADMA Biologics' stock fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, directly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for affected investors, with no out-of-pocket fees required, thereby lowering the barrier for participation in the lawsuit.
- Law Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, raising concerns about the authenticity of the reported 20% revenue growth in 2025, which could undermine investor confidence.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly inflated revenue figures; without this scheme, the company would have faced a 3% revenue decline in 2025 instead of the reported growth.
- Stock Price Plunge: Following these allegations, ADMA Biologics' stock price dropped by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding its financial stability.
- Legal Options for Investors: Investors are encouraged to submit their information for potential legal recourse, with BFA offering representation on a contingency fee basis, thereby reducing the financial burden on affected shareholders and potentially providing avenues for compensation.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against ADMA Biologics for allegedly issuing misleading business information, indicating significant legal risks that could undermine shareholder confidence and stock performance.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, reflecting market concerns over the company's financial transparency.
- Class Action Preparation: Rosen Law Firm is preparing a class action against ADMA, allowing investors to seek compensation without upfront costs, which could impose greater financial strain and reputational damage on the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise, which may encourage more investors to join the lawsuit.
See More
